Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anakinra for COVID-19 Respiratory Symptoms
NCT04364009 · University Hospital, Tours · PHASE3 · terminated · last registry update 2021-01-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Efficiency and safety reasons” | – | Registry record, University Hospital, Tours |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-24Also stopped (terminated): Cale Jacobs, PhD, anakinra (150mg) (NCT02930122)
- 2021-10-27Results posted on the registry: Cale Jacobs, PhD, anakinra (150mg) (NCT02930122)
- 2021-06-30Also stopped (terminated): Swedish Orphan Biovitrum, anakinra + Placebo (NCT03265132)
- 2021-06-11Also stopped (withdrawn): Oslo University Hospital, Anakinra 100 mg in 2 ml saline IA (NCT01997138)
- 2021-05-24Phase 3 first posted: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2021-05-14Also stopped (withdrawn): University of North Carolina, Chapel Hill, Anakinra + Dermatophagoides Farinae (NCT03513458)
- 2021-05-07Also stopped (withdrawn): University of North Carolina, Chapel Hill, Anakinra + Dermatophagoides Farinae (NCT03513471)
- 2021-04-30Results posted on the registry: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Anakinra (NCT01794117)
- 2021-04-30Also stopped (terminated): University of Manchester, Anakinra 100Mg/0.67Ml Inj Syringe (NCT04462757)
- 2021-04-01Phase 3 first posted: University Children's Hospital Basel, Methylprednisolone sodium succinate 10 mg/kg intravenously + Human normal immunoglobulin (IVIg) (NCT04826588)
- 2021-02-23Results posted on the registry: Virginia Commonwealth University, Anakinra + Placebo (NCT03224585)
- 2021-02-23Also stopped (terminated): Virginia Commonwealth University, Anakinra + Placebo (NCT03224585)
- 2020-12-23Phase 3 first posted: Hellenic Institute for the Study of Sepsis, Anakinra + Placebo (NCT04680949)
- 2020-12-16Also stopped (terminated): Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Anakinra alone (stages 2b/3) + Anakinra and Ruxolitinib (overcome stage 3) (NCT04366232)
- 2020-12-10Results posted on the registry: Mack Mitchell, Anakinra + Pentoxifylline (NCT01809132)
- 2020-12-07Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, ANAKINRA + Intravenous immunoglobulin (NCT04656184)
- 2020-11-25Phase 3 first posted: Hamad Medical Corporation, Anakinra (NCT04643678)
- 2020-07-15Results posted on the registry: Swedish Orphan Biovitrum, Anakinra 100 mg + Triamcinolone Acetonide 40 mg (NCT03002974)
- 2020-06-23Phase 3 first posted: Fundacion Miguel Servet, Anakinra 149 MG/ML Prefilled Syringe [Kineret] (NCT04443881)
- 2020-06-09Phase 3 first posted: Assistance Publique Hopitaux De Marseille, Anakinra +/- Ruxolitinib (stages 2b/3) + Anakinra and Ruxolitinib (Advanced stage 3) (NCT04424056)
- 2020-05-11Phase 3 first posted: University of Oxford, Lopinavir-Ritonavir + Corticosteroid (NCT04381936)
- 2020-04-28Results posted on the registry: Swedish Orphan Biovitrum, anakinra + Placebo (NCT03265132)
- 2020-04-24Phase 3 first posted: University of Alabama at Birmingham, Anakinra + Normal saline (NCT04362111)
- 2020-04-01Phase 3 first posted: University Hospital, Ghent, Anakinra + Siltuximab (NCT04330638)
- 2020-03-27Phase 3 first posted: Swedish Orphan Biovitrum, Emapalumab + Anakinra (NCT04324021)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision